In an MDA-MB231 cell xenograft model, MKRN1 deletion results in tumor growth defect after treatment with tumor necrosis factor-related apoptosis inducing ligand (TRAIL), enhancing the sensitivity of triple negative breast cancer to TRAIL treatment [11]. The gene discussed is TNFSF10; the disease is triple-negative breast carcinoma.